Stocks Health care EPRX
NASDAQ · Health careEupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. reported revenue of $0 in fiscal 2025. It posted a net loss of $38.6M. At December 31, 2025 it held $80.6M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 13, 2026.
What Eupraxia Pharmaceuticals Inc. does
Eupraxia Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EPRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$38.6M | -$1.03 | n/a |
| 2024 | $0 | -$25.5M | -$0.76 | n/a |
| 2023 | $0 | -$28.2M | -$1.17 | n/a |
| 2023 | n/a | -$18.5M | -$0.96 | n/a |
Latest SEC filings
What Eupraxia Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- September 2, 2026Form SUPPL filing SUPPL
- August 19, 2026Form F-10/A filing F-10/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 11, 2026
- August 6, 2026Form F-X filing F-X
- August 6, 2026Form F-10 filing F-10
- July 15, 2026
- July 13, 2026
Questions about EPRX
What does Eupraxia Pharmaceuticals Inc. do?
Eupraxia Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EPRX.
Is Eupraxia Pharmaceuticals Inc. profitable?
No. In fiscal 2025 it reported a net loss of $38.6M.
How much revenue does Eupraxia Pharmaceuticals Inc. make?
In fiscal 2025 Eupraxia Pharmaceuticals Inc. reported revenue of $0.
When did Eupraxia Pharmaceuticals Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 13, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 8, 2026.
Similar companies
Follow EPRX
Get an email when Eupraxia Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow EPRX: get an email when it filesWhere the numbers come from
Financial figures are the values Eupraxia Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.